Real-World Study of Bevacizumab Treatment in Patients with Ovarian Cancer: A Chinese single-institution study of 155 patients

Abstract Objective The purpose of this study was to retrospectively assess the pattern, compliance, efficacy and safety of bevacizumab in Chinese ovarian cancer patients. Methods We reviewed the clinicopathological data of patients with histologically confirmed epithelial ovarian cancer, fallopian tube cancer and primary peritoneal adenocarcinoma, who were diagnosed and treated at the Department of Gynecologic Oncology of Peking University Cancer Hospital between May 2012 and January 2022. Results A total of 155 patients were eventually enrolled in this study, with 77 as first-line chemotherapy(FL) and 78 as recurrence therapy(RT). Among the 77 patients in the FL group, 35 received bevacizumab during NACT alone(NT), 23 received bevacizumab during both neoadjuvant and first-line chemotherapy(NT + FL) and 19 received bevacizumab during first-line chemotherapy alone(FLA). Among the 43 patients of NT and NT + FL groups undergoing IDS, 38(88.4%) patients achieved optimally debulking and 24(55.8%) patients had no residual disease after IDS. The patients in the FL group had a median PFS of 15(95%CI: 9.951–20.049) months, and the 12-month PFS was 61.7%. In the RT group, the ORR was 53.8%. According to multivariate analysis, the patients' platinum sensitivity had a significant impact on the PFS in the RT group. 13(8.4%) patients discontinued bevacizumab due to toxicity. The most common adverse event associated with bevacizumab therapy was hypertension. Conclusion Bevacizumab is effective and well-tolerated in the real world setting of ovarian cancer treatment. Adding bevacizumab to NACT is feasible and tolerable. Receiving the regimen containing bevacizumab in the last preoperative chemotherapy did not result in increased intraoperative bleeding of IDS. Platinum sensitivity is the most important factor affecting the effectiveness of bevacizumab in recurrent patients.